Reata Pharmaceuticals (NASDAQ:RETA)‘s stock had its “buy” rating restated by equities research analysts at Cowen in a research note issued to investors on Thursday.
RETA has been the subject of several other research reports. Citigroup reiterated a “buy” rating and issued a $78.00 target price (down previously from $87.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, August 23rd. Jefferies Group initiated coverage on shares of Reata Pharmaceuticals in a research note on Wednesday, August 30th. They issued a “buy” rating and a $44.00 target price for the company. Robert W. Baird reiterated a “buy” rating and issued a $47.00 target price on shares of Reata Pharmaceuticals in a research note on Friday, September 1st. ValuEngine cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 11th. Finally, Leerink Swann initiated coverage on shares of Reata Pharmaceuticals in a research note on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 target price for the company. Three analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. Reata Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $54.71.
Shares of Reata Pharmaceuticals (NASDAQ RETA) traded up $2.83 during trading hours on Thursday, hitting $25.22. The stock had a trading volume of 447,200 shares, compared to its average volume of 126,049. Reata Pharmaceuticals has a 12 month low of $19.48 and a 12 month high of $40.88. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18.
In other Reata Pharmaceuticals news, Director James Edward Bass purchased 3,888 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was purchased at an average price of $24.02 per share, for a total transaction of $93,389.76. Following the completion of the purchase, the director now directly owns 52,089 shares in the company, valued at $1,251,177.78. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 44.00% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in RETA. P.A.W. Capital Corp acquired a new stake in Reata Pharmaceuticals in the third quarter worth $933,000. Swiss National Bank purchased a new stake in shares of Reata Pharmaceuticals in the 2nd quarter worth about $440,000. TIAA CREF Investment Management LLC grew its position in Reata Pharmaceuticals by 39.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,041 shares of the company’s stock valued at $729,000 after purchasing an additional 6,541 shares during the last quarter. Bank of New York Mellon Corp grew its position in Reata Pharmaceuticals by 52.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,959 shares of the company’s stock valued at $1,074,000 after purchasing an additional 11,746 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. purchased a new stake in Reata Pharmaceuticals during the 3rd quarter valued at about $1,866,000. Hedge funds and other institutional investors own 29.61% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.